These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 4015182)

  • 1. Activation of complement by 405-nm light in serum from porphyria cutanea tarda.
    Torinuki W; Miura T; Tagami H
    Arch Dermatol Res; 1985; 277(3):174-8. PubMed ID: 4015182
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activation of the complement system in patients with porphyrias after irradiation in vivo.
    Lim HW; Poh-Fitzpatrick MB; Gigli I
    J Clin Invest; 1984 Dec; 74(6):1961-5. PubMed ID: 6392339
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activation of the alternative complement pathway by 405 nm light in serum from porphyric rat.
    Torinuki W; Miura T; Tagami H
    Acta Derm Venereol; 1984; 64(5):367-72. PubMed ID: 6208712
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Complement-derived chemotactic activity is generated in human serum containing uroporphyrin after irradiation with 405 nm light.
    Lim HW; Perez HD; Goldstein IM; Gigli I
    J Clin Invest; 1981 Apr; 67(4):1072-7. PubMed ID: 7204567
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Complement cleavage products in the phototoxic reaction of porphyria cutanea tarda.
    Pigatto PD; Polenghi MM; Altomare GF; Giacchetti A; Cirillo R; Finzi AF
    Br J Dermatol; 1986 May; 114(5):567-73. PubMed ID: 3487340
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Generation of chemotactic activity in serum from patients with erythropoietic protoporphyria and porphyria cutanea tarda.
    Lim HW; Perez HD; Poh-Fitzpatrick M; Goldstein IM; Gigli I
    N Engl J Med; 1981 Jan; 304(4):212-6. PubMed ID: 7442746
    [No Abstract]   [Full Text] [Related]  

  • 7. Gc-globulin (vitamin D-binding protein) enhances the neutrophil chemotactic activity of C5a and C5a des Arg.
    Kew RR; Webster RO
    J Clin Invest; 1988 Jul; 82(1):364-9. PubMed ID: 3392213
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Complement activation in type 1 human diabetes.
    Sundsmo JS; Papin RA; Wood L; Hirani S; Waldeck N; Buckingham B; Kershnar A; Ascher M; Charles MA
    Clin Immunol Immunopathol; 1985 May; 35(2):211-25. PubMed ID: 3907907
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activation of the alternative complement pathway by Fonsecaea pedrosoi.
    Torinuki W; Okohchi K; Takematsu H; Tagami H
    J Invest Dermatol; 1984 Oct; 83(4):308-10. PubMed ID: 6481182
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Complement activation in cystic fibrosis respiratory fluids: in vivo and in vitro generation of C5a and chemotactic activity.
    Fick RB; Robbins RA; Squier SU; Schoderbek WE; Russ WD
    Pediatr Res; 1986 Dec; 20(12):1258-68. PubMed ID: 3540828
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Photodynamic action of uroporphyrin on the complement system in porphyria cutanea tarda.
    Meurer M; Schulte C; Weiler A; Goerz G
    Arch Dermatol Res; 1985; 277(4):293-8. PubMed ID: 3923948
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Purification of human C5a des arg by immunoadsorbent and molecular sieve chromatography.
    Manderino GL; Suarez AF; Kunkel SL; Ward PA; Hirata AA; Showell H
    J Immunol Methods; 1982 Aug; 53(1):41-50. PubMed ID: 6752282
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemotactic peptides modulate adherence of human polymorphonuclear leukocytes to monolayers of cultured endothelial cells.
    Charo IF; Yuen C; Perez HD; Goldstein IM
    J Immunol; 1986 May; 136(9):3412-9. PubMed ID: 3514759
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanisms of phototoxicity in porphyria cutanea tarda and erythropoietic protoporphyria.
    Lim HW
    Immunol Ser; 1989; 46():671-85. PubMed ID: 2488874
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Erythropoietic protoporphyria. Photoactivation of the complement system.
    Gigli I; Schothorst AA; Soter NA; Pathak MA
    J Clin Invest; 1980 Sep; 66(3):517-22. PubMed ID: 7400327
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemotactic responses of human peripheral blood monocytes to the complement-derived peptides C5a and C5a des Arg.
    Marder SR; Chenoweth DE; Goldstein IM; Perez HD
    J Immunol; 1985 May; 134(5):3325-31. PubMed ID: 3884709
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Group B streptococci inhibit the chemotactic activity of the fifth component of complement.
    Hill HR; Bohnsack JF; Morris EZ; Augustine NH; Parker CJ; Cleary PP; Wu JT
    J Immunol; 1988 Nov; 141(10):3551-6. PubMed ID: 3053900
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The chemotactic activity of normal and complement-activated serum as measured by the leading-front method using a Boyden chamber.
    Håkansson L; Venge P
    Scand J Immunol; 1984 Jan; 19(1):63-73. PubMed ID: 6367020
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biologically active products of complement and acute lung injury in patients with the sepsis syndrome.
    Weinberg PF; Matthay MA; Webster RO; Roskos KV; Goldstein IM; Murray JF
    Am Rev Respir Dis; 1984 Nov; 130(5):791-6. PubMed ID: 6497161
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stratum corneum activation of complement through the antibody-independent alternative pathway.
    Terui T; Kato T; Tagami H
    J Invest Dermatol; 1989 Apr; 92(4):593-7. PubMed ID: 2649596
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.